Sarcoidosis Induced by Tocilizumab: A Paradoxical Event?

To the Editor:

Tocilizumab (TCZ) is a monoclonal antibody against the interleukin 6 (IL-6) receptor, used in the treatment of rheumatoid arthritis (RA). We describe a case of onset of sarcoidosis under TCZ therapy in a patient with RA.

A 40-year-old woman of North African origin had RA for 12 years. Rheumatoid factor and anticitrullinated antibody were negative. Erosions were absent. Nevertheless, she fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) RA classification criteria (7/10). She was refractory to sulfasalazine and then to methotrexate (MTX). Etanercept was introduced in 2008 and stopped in 2010 because of secondary loss of efficacy. TCZ was initiated in April 2010. The response was good, with the 28-joint Disease Activity Score (DAS28) 0.5 and Health Assessment Questionnaire 0.25 in June 2012, without intolerance. In August 2012, during a stay in Morocco, she developed painful cutaneous nodules, 4 on arms and 2 on legs, with an 8-kg weight loss. Articular symptoms were controlled.

Cutaneous biopsy of arms and legs was performed. Fungal, bacterial, and mycrobacterial cultures were negative and histological examination revealed noncaseating epithelioid granulomas in the hypodermis (Figure 1). Tuberculin skin test and QuantiFeron were negative. Angiotensin-converting enzyme was mildly elevated at 70 IU/l (n = 0-68 IU/l). A chest computed tomography showed symmetrical hilar and mediastinal lymph nodes, the largest lymph node measuring > 1 cm (Figure 2). A left paratracheal and mediastinal lymphadenopathy aspirate biopsy showed 2 noninfective epithelioid granulomas. The diagnosis of cutaneous and pulmonary sarcoidosis was considered. Infection, including tuberculosis, was ruled out and histological analysis was consistent with sarcoidosis. She did not develop dyspnea, dry cough, kidney involvement, eye involvement, or cardiac lesions.

TCZ was discontinued and RA flared (DAS28 = 5.53). Metacarpophalangeal and interphalangeal joints and knees were swollen and painful. C-reactive protein and erythrocyte sedimentation rates were elevated, 17.0 mg/l and 27 mm, respectively. Prednisone was introduced (10 mg/day) with good efficiency on RA and cutaneous nodules. Because of pulmonary involvement, we decided not to restart TCZ and introduced certolizumab with good efficacy and safety.

This patient presented with RA with synovitis and tenosynovitis, without evidence for osteoarticular sarcoidosis. However, the hypothesis of initial sarcoidosis and not RA is possible because of good response to anti-tumor necrosis factor-α (anti-TNF). Nevertheless, it seems less likely because of presence of RA symptoms according to ACR/EULAR criteria and the efficacy of tocilizumab until cessation. To our knowledge, this is the first case of an occurrence of sarcoidosis during TCZ therapy.

It is of interest that sarcoidosis did not appear when the patient was treated with etanercept and, to date, did not flare with certolizumab. Paradoxical effects have been described with TNF blockers, including psoriasis1, lupus2, vasculitis3, and sarcoidosis4.

Sarcoidosis is a systemic granulomatous disorder characterized by an accumulation of T cells and macrophages, activated by various cytokines. We observed a local Th1/Th2 imbalance in favor of Th1-related cytokine expression, like IL-2, interferon gamma, TNF, or IL-6. IL-6 is a macrophage/monocyte-derived cytokine and plays a role in the promotion and maintenance of sarcoïd granulomatous inflammation through the activation of CD4+ T cells5. In patients with sarcoidosis, IL-6 is increased in bronchoalveolar fluid6 and in urine from patients with acute renal failure7. IL-6 blockers should have a protective role in sarcoidosis.

Finally, other possible induced events have been reported with TCZ, such as eye inflammation including uveitis8, onset of psoriasis9, and immune complex-mediated glomerulonephritis10.

Our case could represent a new example of paradoxical events with TCZ and suggests the possibility of diseases induced by TCZ therapy.

REFERENCES


J Rheumatol 2013;40:10; doi:10.3899/jrheum.130278